Kuickresearch::Industry News

1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50 | 51 | 52 | 53 | 54 | 55 | 56 | 57 | 58 | 59 | 60 | 61 | 62 | 63 | 64 | 65 | 66 | 67 | 68 | 69 | 70 | 71 | 72 | 73 | 74 | 75 | 76 | 77 | 78 | 79 | 80 | 81 | 82 | 83 | 84 | 85 | 86 | 87 | 88 | 89 | 90 | 91 |

Emergence Of Next Generation Cancer Therapies

Release Date: 08 November 2024

The existing cancer therapies domain is undergoing a significant transformation due to the introduction of novel therapies, offering renewed hope to patients suffering from previously untreatable or resistant forms of the...

Read More


Tetraspecific Antibodies Clinical Development Insight

Release Date: 08 November 2024

The rapid advancements in immunotherapy, particularly antibody therapies, have paved the way for innovative approaches like tetraspecific antibodies. These unique molecules can bind to four different targets simultaneousl...

Read More


Bispecific Antibody Drug Conjugates For Cancer

Release Date: 07 November 2024

Bispecific antibody drug conjugates (BsADCs) represent a groundbreaking innovation in targeted cancer therapy, combining the specificity of bispecific antibodies with the potent delivery mechanisms of drug conjugates. The...

Read More


Cancer Antibody Drug Conjugates Sales To Surpass USD 13 Billion In 2024

Release Date: 23 October 2024

The global cancer antibody-drug conjugate (ADC) market is poised for significant growth in 2024. Following a robust valuation of approximately US$ 10 billion in 2023, the market is projected to surpass US$ 13 billion by t...

Read More


Antibody Drug Conjugates For Lung Cancer

Release Date: 22 October 2024

Antibody drug conjugates (ADCs) are emerging as a promising approach in the treatment of lung cancer, particularly non-small cell lung cancer (NSCLC). Currently, there is only one approved ADC for lung cancer, with two ot...

Read More


PROTAC Therapy PROTAC Drugs Clinical Trials PROTAC Therapy Market Insight

Release Date: 11 October 2024

PROTACs, or proteolysis-targeting chimeras, represent a transformative approach in the field of therapeutic development, offering a novel mechanism for targeting disease-causing proteins. Unlike traditional small molecules that inhibit p...

Read More


PROTAC Therapy for Breast Cancer

Release Date: 11 October 2024

Breast cancer remains one of the most prevalent forms of cancer worldwide, affecting millions of women each year. Advances in treatment, such as hormonal therapies, chemotherapy, radiation, and targeted therapies, have si...

Read More


PROTAC Drugs Overcoming Cancer Drug Resistance

Release Date: 11 October 2024

Cancer drug resistance remains one of the most significant challenges in oncology, limiting the effectiveness of many therapies. Tumors often develop mechanisms to evade or resist treatment, resulting in disease progressi...

Read More


PROTACs In Cancer Therapy

Release Date: 10 October 2024

The advent of Proteolysis-Targeting Chimeras (PROTACs) has marked a significant leap forward in the field of targeted cancer therapy. Traditional cancer treatments often rely on small molecule inhibitors, which function b...

Read More


PIM Kinase Inhibitors Therapies Clinical Trials Market Size FDA Approval Insight

Release Date: 04 October 2024

Precision medicine has heralded a novel epoch of change as well as challenge in the treatment of patients with cancer. Despite the fact that immunotherapies and targeted therapies have significantly improved the individua...

Read More


PRMT5 Inhibitor Therapy Clinical Trials FDA Approval Market Size

Release Date: 04 October 2024

In the dynamic landscape of cancer therapeutics, the emergence of precision medicine has revolutionized treatment paradigms, offering tailored approaches that capitalize on the unique molecular signatures of individual tu...

Read More


Anti CD70 Antibodies Clinical Trials FDA Approval Market Size Companies Insight

Release Date: 04 October 2024

In recent decades, advancements in immunology have led to the identification of novel immune checkpoints, significantly revitalizing cancer immunotherapy. One of the most promising candidates is the CD70 protein, which is...

Read More


DLL3 Targeted Cancer Therapy Clinical Trials Market Size FDA Approval Insight

Release Date: 04 October 2024

The pursuit of precision medicine has ushered in new possibilities for tailored therapies within the elaborate landscape of cancer treatment. Targeting Delta-Like Ligand 3 (DLL3) in cancer cells stands out as a particular...

Read More


Global Tetraspecific Antibodies Clinical Trials FDA Approval Overview

Release Date: 26 September 2024

For an extended period, the awareness of immunotherapy has been related to targeting novel and unique agents and inhibiting their function. Compelling this hypothesis, researchers, in conjunction with scientists and docto...

Read More


India Cancer Diagnostic Test Cancer Screening Market Size

Release Date: 26 September 2024

In the vast tapestry of India's healthcare landscape, the diagnostics industry has experienced remarkable growth, particularly in the sector of cancer diagnostics. This surge can be attributed to the increasing prevalence...

Read More


1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50 | 51 | 52 | 53 | 54 | 55 | 56 | 57 | 58 | 59 | 60 | 61 | 62 | 63 | 64 | 65 | 66 | 67 | 68 | 69 | 70 | 71 | 72 | 73 | 74 | 75 | 76 | 77 | 78 | 79 | 80 | 81 | 82 | 83 | 84 | 85 | 86 | 87 | 88 | 89 | 90 | 91 |

Need custom market research solution? We can help you with that too.